Transgene chooses PathoQuest innovative NGS-based safety release test for TG4050 phase I clinical trial targeting patients with head-neck and ovarian cancers and for Invir.IO™ platform for recombinant viral vector manufacturing.

Transgene is a French biotechnology company focused on designing and developing next generation immunotherapeutics. In these phase 1 trials with 85 patients, Transgene has chosen PathoQuest next generation sequencing (NGS) solutions for its fast and cost-effective...

PathoQuest named 32nd most inventive start-up in France

100brevets.tech - Inventors of the French Tech Awards - has ranked PathoQuest as the 32nd most inventive start-up based in France and the 7th ranked MedTech company. See the list in as reported by Forbes at http://bit.ly/pathoquest-no32. .    ...

PathoQuest Secures 8 Million Euros in New Financing

Paris, FRANCE -- (BUSINESS WIRE) -- September 5, 2019 -- PathoQuest, a genomic expert company dedicated to the microbiology testing market and a leader in clinical diagnostics and biologics testing applications, today announces the closing of an 8M euros financing...